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In recent years, there has been an increasing interest in interactive application principles of biology and engineering for the
development of valid biological systems for tissue regeneration, such as for the treatment of bone fractures or skeletal defects.
The application of stem cells together with biomaterials releasing bioactive factors promotes the formation of bone tissue by
inducing proliferation and/or cell differentiation. In this study, we used a clonal cell line from human adipose tissue-derived
mesenchymal stem cells (hADSCs or preadipocytes), named PA2-E12, to evaluate the effects of strontium (Sr2+) released in
the culture medium from an amidated carboxymethylcellulose (CMCA) hydrogel enriched with different Sr2+ concentrations
on osteodifferentiation. The osteoinductive effect was evaluated through both the expression of alkaline phophatase (ALP) activity
and the hydroxyapatite (HA) production during 42 days of induction. Present data have shown that Sr2+ released from CMCA
promotes the osteodifferentiation induced by an osteogenic medium as shown by the increase of ALP activity at 7 and 14 days and
of HA production at 14 days. In conclusion, the use of biomaterials able to release in situ osteoinductive agents, like Sr2+, could
represent a new strategy for future applications in bone tissue engineering.
1. Introduction
The repair of large bone defects, due to trauma, tumors,
and/or congenital malformations is a global health prob-
lem and a major challenge for orthopaedic surgery [1–
4]. Current treatment options include surgical reconstruc-
tion by organ/tissue transplantation of autografts/allografts.
These traditional methods are often associated with lim-
ited availability in autografts, and risk of immunogenicity,
infection, and local pain [5, 6]. Today, tissue engineering
by artificial tissue grafts represents a valid alternative for
overcoming the therapeutic and methodological limitations
of current therapy [7–11]. The aim of tissue engineering
is to produce functional tissues in vitro [1], in order to
improve in vivo regeneration using cells, biodegradable
biomaterials/scaffolds, and bioactive factors [10, 12–16]. The
advantage of this approach is that it can reduce the number
of surgical operations and the time of recovery for solving the
clinical problems.
Scaffolds are key components acting as a mold for
interaction with the cells, also providing support for cell
adhesion, growth, and differentiation. A good scaffold has to
be osteoconductive (to induce the cells to adhere, migrate,
and proliferate), osteoinductive (to be able to induce pro-
liferation of undifferentiated cells and their subsequent dif-
ferentiation into osteoblasts), biocompatible, and biodegrad-
able [17]. Moreover, a scaffold must possess mechanical
properties similar to the native tissue to be repaired. A
further requirement for a scaffold, particularly in bone
engineering, is a controllable interconnected porosity to
promote engraftment, proliferation, and migration of bone
cells, as well as synthesis of the extracellular matrix (ECM),
vascularization of the ingrown tissue, and interconnection
between the implant and the bone tissue, in order to ensure
mechanical stability [14, 18, 19]. In addition, the mechanical
properties of the scaffold must be sufficient and not collapse
during handling and during the patient’s normal activities.
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Finally, the scaffold must be easily sterilizable to prevent
infections [20].
The other component for the engineering of a viable
tissue construct is the use of cell therapy. Mesenchymal stem
cells (MSCs), given their osteoblast-driven differentiation
potential, represent the most suitable cell source in bone
regeneration therapies. MSCs are multipotent cells identified
in numerous tissues such as bone marrow, fat, placenta,
umbilical cord, human amniotic fluid, dental pulp, and
skeletal muscle [21–28]. Many studies have demonstrated the
usefulness of MSCs for regenerative medicine, in particular
in osteoarticular disorders [29]. MSCs, isolated from adult
bone marrow (BMMSCs), can be induced in vitro and
in vivo to differentiate into various mesenchymal lineages
(bone, cartilage, tendon, adipose tissue, and muscle). These
cells can also differentiate into nonmesenchymal cell lines,
such as endothelial cells [30], cardiac myoblasts [31],
neuronal cells [32], and hepatocytes [33]. BMMSCs have
been demonstrated to stimulate bone formation in skeletal
defects and nonunion, through cytokines and growth factors
secreted by the transplanted cells [34, 35]. Recent studies
have demonstrated that also human adipose tissue-derived
mesenchymal stem cells (hADSCs) are able to differentiate
into active osteoblasts, like their bone marrow counterpart
(hBMMSCs) [36–38]. These characteristics, together with
the greater quantity obtainable and the low invasiveness of
fat sampling procedure, make adipose tissue an excellent cell
source for bone regeneration [38].
Several studies have investigated the applicability of
hydrogels, water-soluble polymers which swell to form a
gel-like substance upon exposure to water [39, 40], acting
as biodegradable and biocompatible scaffolds for bone
grafts and cartilage regeneration [41–48]. In vitro studies
have demonstrated that amidated carboxymethyl cellulose
(CMCA) hydrogel is a potential filler for cartilage defects.
Normal human articular chondrocytes seeded on CMCA
[48] promote synthesis of ECM components, significantly
increasing production of both type II collagen and aggregan,
the hallmark proteoglycan for hyaline cartilage [49]. These
data suggest that CMCA hydrogels could represent a good
support for tissue engineering in osteoarticular disorders
[48]. Currently, attention has been focused on the use of
scaffolds enriched with bioactive factors such as biologically
active proteins, growth factors, hormones, cytokines, and
drugs capable of inducing cell proliferation and/or differenti-
ation [50–54]. Moreover, the addition of anti-inflammatory
drugs and antibiotics can make the prevention of infections
after surgery possible [55].
An agent registered as an antifracture drug is strontium
ranelate (SR), whose active component on bone remodelling
is the Sr2+ ion [56–58]. Unlike all the other treatments for
osteoporosis, SR has a dual effect on bone remodelling,
being able, simultaneously, to stimulate osteoblast-mediated
bone formation and to inhibit osteoclast-induced bone
resorption [59]. Indeed, SR stimulates in vitro osteoblastic
differentiation markers such as alkaline phosphatase (ALP),
bone sialoprotein, and osteocalcin (OCN) and also inhibits
the proliferation of osteoclast precursors as well as osteoclas-
togenesis [60, 61].
In vitro studies have shown that the use of biomaterials
enriched with Sr2+ is promising. In fact, strontium-doped-
calcium-polyphosphate-(SCPP) based bioceramic scaffolds
combined with the rat osteosarcoma cell line ROS17/2,8
promoted cell proliferation and induced mRNA expression
and release of two angiogenic factors, vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor
(bFGF) [62–64].
The encouraging results obtained by the use of cells
combined with hydrogels and by the use of scaffolds enriched
with Sr2+ on the in vitro osteogenic differentiation of
hADSCs, prompted us to perform a study on the combined
use of hydrogels and Sr2+, to assess its potential for future
applications in bone tissue engineering.
2. Materials and Methods
2.1. CMCA Hydrogel and CMCA Hydrogel Enriched with
Sr2+ Preparation. The CMCA hydrogel and CMCA hydrogel
enriched with Sr2+ used in this study were obtained from
BioSuMa (Lima Corporate S.p.a., Villanova di San Daniele
del Friuli, Italy). The procedure for the realization of amidic
derivative of CMC-based hydrogel (CMCA) was previously
reported [65]. The kinetics of degradation in vitro of CMCA
hydrogel were evaluated at 7 days by hyialuronidase and
β-mannosidase enzymes with percentages of degradation,
respectively, of 7% and 32% [experimental data not shown,
provided by R. Barbucci (C.R.I.S.M.A) University of Siena].
The preparation of CMCA enriched with Sr2+ was carried
out by bulge of gel in aqueous solutions of 3, 30, 300 μM
and 3mM SrCl2, exploiting the property of hydrogel to
incorporate a large quantity of water. The hydrogel enriched
with Sr2+ was stratified in transwell 6-well Millicell inserts
(Millipore) with 2.5 cm diameter, dehydrated, and sterilized
by ethylene oxide. The evaluation of the amount of Sr2+
incorporated in the hydrogel and then released into the
medium was carried out by inductively coupled plasma mass
spectrometry (ICPMS) technique that uses an ICP torch to
produce the ionization, and a mass spectrometer to separate
and detect the ions produced [66].
2.2. Cell Culture. A primary cell line of hADSCs, named
PA2, previously cultured and characterized for its multi-
potency in our laboratory [39], was plated on tissue
culture polystyrene (tPS) substrate at 37◦C in humidified
atmosphere with 5% CO2 in growth medium (GM) [Ham’s
F12 Coon’s modification medium supplemented with 10%
fetal calf serum (FCS), 100 IU/mL penicillin, 100 μg/mL
streptomycin, and 1 ng/mL basic fibroblast growth factor
(bFGF)]. The medium was refreshed twice a week and cells
were used for further subculturing or cryopreservation upon
reaching 5 × 103 cells/cm2.
2.3. Cell Cloning. The primary cell line PA2 at the 3rd
passage were used for cell cloning. Cells in active phase of
growth were cloned by the dilution plating technique. Cells
were detached with trypsin 1 : 250 0.4mg/mL in Dulbecco’s
phosphate-buffered saline (DPBS) without Ca2+ without
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Mg2+ with EDTA 0.2mg/mL and with glucose 1mg/mL,
resuspended in Coon’s medium + 20% FCS. The cell
suspension was diluted to a concentration of 10 cells/mL
in the following cloning medium: Coon’s medium + 20%
FCS supplemented with 25% conditioned medium prepared
from human fetal fibroblast culture. The cell suspension was
maintained in agitation and 0.1mL was rapidly distributed
per well of a 96-multiwell plate. Each well was carefully
observed and the wells containing only one cell were scored.
The cloning culture was incubated at 37◦C in humidified air
with 5%CO2.When colonies reached the consistency of 500–
600 cells, they were detached, collected, and first transferred
in 24-multiwell plates and subsequently expanded in 60mm
and 100mm dishes. Seven finite clonal lines, named PA2-C5,
PA2-D4, PA2-E12, PA2-F2, and PA2-H8, were obtained from
the PA2 cell line. PA2-E12 was chosen among these finite
clonal cell lines for its high proliferative capacity.
2.4. Clonal Cell Line Characterization. The characterization
of PA2-E12 finite clonal cell line, to verify its multi-potency,
was performed by studying the adipogenic and osteogenic
differentiation, as previously described [38].
2.5. Adhesion and Morphology Analysis. CMCA hydrogel
was sterilized by ethanol, balanced in GM, and afterwards
distributed on tPS. The plates coated with CMCA hydrogel
were preincubated at 37◦C in humidified atmosphere with
5% CO2 in GM for 4 h. Thereafter, PA2-E12 cells were
cultured in GM and seeded on CMCA hydrogel. PA2-E12
cells cultured on CMCA hydrogel were evaluated for cell
morphology and capacity to adhere to CMCA hydrogel after
1, 3, 6, 9, 12, and 15 days from seeding. Total cellular RNA
was isolated both from cells cultured in GM on tPS and cells
cultured in GM on CMCA hydrogel during time of culture.
2.6. Osteogenic Differentiation in Presence of CMCA Hydrogel
Enriched with Sr2+. PA2-E12 cells were previously seeded at
semiconfluence on tPS in 6-multiwell plates at a cell density
of 1 × 104 cells/cm2 in GM. After 3 days at achievement
of confluence, the cells were differentiated by on osteogenic
medium (OM): Coon’s medium supplemented with 10%
FCS, 100 IU/mL penicillin, 100 μg/mL streptomycin, 10 nM
dexamethasone, 10mM β-glycerophosphate, and 200mM
sodium L-ascorbyl-2-phosphate. The osteogenic differentia-
tion was carried out in OM in the presence of 3 μM–3mM
Sr2+. In parallel, experiments in OM were carried out in the
presence of transwell containing CMCA hydrogel enriched
with 0, 3, 30, 300 μM and 3mM Sr2+. The medium was
refreshed twice a week. The expression of the osteoblastic
phenotype was evaluated quantitatively by ALP activity and
by hydroxyapatite (HA) production at different times from 1
to 42 days of culture and respective values were normalized
by DNA content/well. For ALP assay, each well was incubated
with 500 μL of 4-methylumbelliferyl phosphate in 280mM
Tris-HCl buffer pH 9.0 for 15min at 37◦C. The reaction
was stopped by the addition of 2mL of 0.1M NaOH.
ALP activity was measured with a spectrofluorometer LS55
(PerkinElmer) at 365 nm λ excitation and 445 nm λ emission
and expressed in μU ALP/ng DNA using a standard curve
of 4-methylumbelliferone 50 nM–10 μM in 280mM Tris-
HCl buffer pH 9.0. For HA assay, cells were grown in OM
containing 1mg/mL calcein, fixed and washed. Afterwards,
each well was incubated with 2mL of 50mM NaEDTA
for 30min at 37◦C, then the fluorescence was measured
with spectrofluorometer LS55 (PerkinElmer) at 494 nm λ
excitation and 517 nm λ emission and expressed in μg HA/ng
DNA using a standard curve of HA 25 ng/mL–500 μg/mL
solubilized in 50mM NaEDTA. A cytochemical evaluation
for ALP was carried out at 14 days of culture using a method
of simultaneous coupling between naphthol and diazonium
salt to obtain an azoic dye. The cells were washed with
DPBS (two times), stained with a specific dye mixture (5mg
Naphthol-AS-MX phosphate sodium salt dissolved in 1mL
dimethyl sulfoxide), 40mg fast red violet LB dissolved in
49mL Tris-HCl buffer 280mM pH 9.0 for 30min at 37◦C.
Then, the cells were washed with DPBS (two times, fixed in
4% paraformaldehyde (PFA)/DPBS for 15min and washed
with ultrapure water three times). ALP+ cells were stained
in red. No staining was carried out to highlight HA deposits
that result in black because of their optical density property
in transmitted light.
2.7. Statistical Analysis. The statistical significance of dif-
ferences between mean values of ALP activity and of HA
deposits production between controls and stimuli were
evaluated by two-tailed Student’s t-test on experiments
repeated three times and carried out in quadruplicate.
3. Results
3.1. Adhesion and Cellular Morphology. PA2-E12 cultured
in GM on tPS (controls) showed an optimal adhesion to
the surface with a fusiform shape after 1 day of culture
(Figure 1(a)). PA2-E12 cultured on CMCA hydrogels showed
a round morphology and a limited adhesion on CMCA
hydrogels after 1 day of culture (Figure 1(b)). Total RNA
of cells cultured in GM on tPS increased during time of
culture (1–15 days) with cellular proliferation and the cells
maintained a fusiform shape. Total RNA of cells adherent to
hydrogel was constant during time of culture (1–15 days),
but it was near to the lower limit detectable due to low
number of cells adherent to hydrogel.
3.2. Sr2+ Loading on CMCA Hydrogel and Sr2+ Release and
Accumulation in the CultureMedium. The percentage of Sr2+
incorporation in the CMCA hydrogel was 95% of the total
exposure and the Sr2+ released in the culture medium at
37◦C for each hour resulted to be of the order of 2% the ion
incorporated into the hydrogel. The Sr2+ was accumulated in
the culture medium until the replacement of the old medium
with fresh medium (Table 1). During time of culture of cells,
CMCA hydrogel showed no alteration or degradation signs
in the structure 3D by microscopic observation.
3.3. Effects of Sr2+ Dissolved Directly in OM and of Sr2+
Released from CMCA Hydrogel in OM on ALP Activity.
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Table 1: Release and accumulation of Sr2+ in the culture medium from transwells with CMCA enriched with Sr2+.
Days of
culture
[Sr2+] accumulated in
the culture medium in
presence of CMCA
enriched with 3mM Sr2+
[Sr2+] accumulated in the
culture medium in
presence of CMCA
enriched with 300 μM Sr2+
[Sr2+] accumulated in the
culture medium in
presence of CMCA
enriched with 30 μM Sr2+
[Sr2+] accumulated in
the culture medium in
presence of CMCA
enriched with 3 μM Sr2+
Replacement of the
old OM with fresh
OM
1 1095± 33 mM 110± 3 µM 12± 0.4 µM <3 µM
2 1769 ± 68mM 172 ± 5 μM 19 ± 0.5 μM <3 μM
3 2185 ± 76mM 220 ± 6 μM 20 ± 0.5 μM <3 μM X
4 256 ± 8 μM 24 ± 0.7 μM 2.6 ± 0.1 μM <3 μM
5 413 ± 8 μM 43 ± 1.1 μM 4.2 ± 0.1 μM <3 μM
6 510 ± 14 μM 50 ± 1.6 μM 5.1 ± 0.2 μM <3 μM
7 570± 16 µM 59± 1.5 µM 6.0± 0.2 µM <3 µM X
8 37 ± 1 μM 3.6 ± 0.1 μM <3 μM <3 μM
9 59 ± 2 μM 6.0 ± 0.2 μM <3 μM <3 μM
10 73 ± 2 μM 7.2 ± 0.2 μM <3 μM <3 μM X
11 9 ± 0.3 μM <3 μM <3 μM <3 μM
12 14 ± 0.4 μM <3 μM <3 μM <3 μM
13 17 ± 0.6 μM <3 μM <3 μM <3 μM
14 19± 0.6 µM <3 µM <3 µM <3 µM X
17 <3 μM <3 μM <3 μM <3 μM X
21 <3 μM <3 μM <3 μM <3 μM X
28 <3 µM <3 µM <3 µM <3 µM X
42 <3 µM <3 µM <3 µM <3 µM X
Values expressed as means ± SD of Sr2+ at times for quantitative ALP and HA analysis are indicated in bold.
(a) (b)
Figure 1: (a) Phase-contrast microscopy (20x objective) of PA2-E12 cultured in GM on tPS after 1 day of culture. (b) Phase-contrast
microscopy (20x objective) of PA2-E12 on CMCA hydrogels after 1 day of culture.
An increasing ALP activity was measured from 1 to 14
days in all samples with a decreasing trend afterwards. The
production of ALP was always present in all samples after
42 days with mean increases of 282% compared to 1 day
of induction. Significant increases of ALP activity versus
controls were observed in cells cultured in OM in presence of
Sr2+ released from CMCA hydrogel enriched with 3mM Sr2+
(corresponding to culturemedium concentrations of 600 μM
after 7 days of culture, 20 μM after 14 days, and 20 nM after
28 days) with maximum percent increase of 99% after 14
days (Figure 2). Conversely, in CMCA hydrogel enriched
with 0, 3, 30 and 300 μM Sr2+, no effect was observed on ALP
induction (Figure 2).
Similarly, in cells cultured in OM containing 300 μM and
3mM Sr2+, significant increases compared to controls were
observed after 7 and 14 days (maximal increases after 14 days
for 300 μM and 3mM Sr2+, resp., 85% and 106%), with a
prolonged effect up to 28 days only in the presence of 3mM
Sr2+. As expected, significant increases of ALP activity were
not observed in cells cultured in OM containing 3 or 30 μM
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Figure 2: Quantitative analysis of ALP enzymic activity in PA2-E12 cultured on tPS from 1 to 42 days in OM in the presence of transwell con-
taining CMCA hydrogel (T-G) enriched with scalar concentrations of strontium (T-G 0, 3, 30, 300 μM and 3mM Sr2+) or in OM only con-
taining scalar concentrations of strontium (3, 30, 300 μM and 3mM Sr2+). The control is represented by cells cultured in OM without Sr2+.
Sr2+. After 42 days of induction, ALP activity decreased
in all samples, without significant differences compared to
controls (Figure 2).
3.4. Effects of Sr2+ Dissolved Directly in OM and of Sr2+
Released from CMCA Hydrogel in OM on the Formation
HA Deposits. The formation of HA deposits begins to be
observed after 14 days, increasing during time up to 42
days of culture. Low concentrations of Sr2 directly dissolved
in OM did not modify the progression of HA deposition,
while at 300 μM and 3mM Sr+2 the accumulation of HA
was dramatically reduced at all analyzed times. Conversely,
for cells cultured with 30 μM Sr2+ directly dissolved in OM,
significant increases of HA deposits compared to control
were observed only after 14 days with percent increase of
+98%. Similarly, at 14 days, significant increases of HA
deposits formation were observed for cells cultured in OM
in the presence of Sr2+ released from the CMCA hydrogel
enriched with 3mM Sr+2 and accumulated in the culture
medium at a final concentration of 20 μM Sr+2 (Table 1)
with percent increase: 169% versus control. After 28 and
42 days, no significant differences compared to control
were observed for cells cultured with Sr2+-enriched CMCA
hydrogel (Figure 3).
3.5. ALP and HA Activity. According to the results obtained
with the quantitative ALP and HA analysis, 3mM Sr2+
concentration loaded on CMCA hydrogel and 30 μM Sr2+
concentration directly added to OM were used for light
microscopy observation. A similar qualitative osteogenic
differentiation was observed at 14 days in cells cultured on
tPS in OM in the presence of 3mM Sr2+-enriched CMCA
hydrogel, in the presence of 30 μM Sr2+ added directly to the
OM, and in the presence of control OM alone (Figure 4). In
all the three conditions an initial formation of HA deposits
was observed with a higher density in the presence of Sr2+
ion, with cell groups at different staining intensity for ALP
activity being present in all conditions, but more abundant
in the presence of the Sr2+ ion(Figure 4).
4. Discussion
The interaction between stem cells and biomaterials repre-
sents an innovation in the tissue-engineered field for the
replacement of damaged bone tissues, representing a great
challenge for orthopaedic surgeons in the repair of bone
and/or cartilage large defects. To offer the best opportunities
for bone tissue repair innovation, the development of both
novel biomaterials and ideal cell models is needed.
The design of biomimetic materials for the development
of biomaterials is an area of great interest for tissue engineer-
ing applications [67–69]. Biomaterials can be coated with
bioactive molecules that can serve as an artificial extracellular
matrix (ECM) providing suitable background to promote
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Figure 3: Quantitative analysis of the formation of HA deposits in PA2-E12 cultured on tPS from 1 to 42 days in OM in presence of transwell
containing CMCA hydrogel (T-G) enriched with scalar concentrations of strontium (T-G 0, 3, 30, 300 μM and 3mM Sr2+) or in OM only
containing scalar concentrations of strontium (3, 30, 300 μM and 3mM Sr2+). The control is represented by cells cultured in OM without
Sr2+.
cell adhesion and proliferation [70]. The surface modifica-
tion of biomaterials, coated with bioactive molecules, can be
made using long chains of ECM proteins such as fibronectin
(FN) and laminin (LN), or a short peptide such as Arg-Gly-
Asp (RGD) derived from FN and LN [53]. Hydrogels are able
to protect drugs, peptides, and especially proteins against the
potentially harsh surrounding microenvironment [71].
In this paper, CMCA hydrogels used in combination with
PA2-E12, a clonal cell line obtained from a hADSCs line,
did not result to be suitable to promote cell adhesion, as
a consequence of basal chemical structure hydrogels, and
determined a rounded cell morphology. In literature, data
have shown that the hydrogel’s surface must be chemically or
biologically engineered (e.g., with the addition of adhesion
ligands, short fragments of bioactive molecules) to obtain
good bioactivity [72, 73].
The presence of CMCA hydrogel in the transwell for the
PA2-E12 cells cultured on tPS did not modify the osteogenic
characteristics of these cells, with no interference to the
osteogenic differentiation process and without toxic effects.
These data obtained on the biocompatibility have shown that
CMCA hydrogels had the characteristics to be modified with
the addition of bioactive molecules. In fact, we havemodified
the characteristics of hydrogel with addition of different
concentrations of Sr2+ to investigate the effects of strontium
release from CMCA hydrogel on the osteodifferentiation
of PA2-E12 cells. The 3mM Sr2+ concentration loaded on
CMCA hydrogel was able to promote the osteodifferentiation
of PA2-E12 cells, as shown by increased ALP activity at 7 and
14 days compared to OM. Moreover, at 7 days the response
of ALP production in CMCA enriched with 3mM Sr2+ was
analogous to that of the cells cultured in OM with 3mM
Sr2+, probably due to an initial high release of Sr2+ in culture
medium, able to more quickly direct the osteodifferentiation
of the PA2-E12. CMCA hydrogel enriched with 3mM Sr2+
was also able to promote the formation of HA deposits, as
shown by increased HA activity at 14 days compared to OM.
This response was similar to that obtained with the cells
cultured in OM with 30 μM Sr2+, probably due to the similar
Sr2+ concentrations present in the culture medium. In fact,
at 14 days the Sr2+ concentrations accumulated in the culture
medium after release from the hydrogel enriched with 3mM
of Sr2+ was about 20 μM. These results are confirmed by
qualitative analysis of ALP activity and of HA formation
for PA2-E12 cells with light microscopy observation after
staining. In fact, 3mM Sr2+ loaded in CMCA and 30 μMSr2+
directly added to OM, the more responsive concentrations
of Sr2+ resulting from the quantitative analysis, were able to
increase the number of ALP+ cells and the density of HA
deposits compared to control at 14 days of osteoinduction.
The higher doses (e.g., 300 μM and 3mM) of Sr2+ in
the cells cultured on tPS seem to inhibit the formation of
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Figure 4: PA2-E12 cultured on tPS for 14 days in OM alone (a), in OM added with 30 μM Sr2+ (b), and without in the presence of gel-
enriched with 3mM Sr2+ (c). Cells fixed and stained for ALP. Observation in brightfield microscopy (10x objective): ALP+ cells intensity in
red, ALP− cells in yellow, and HA deposits in black (green arrows).
HA deposits presupposing alterations of the physicochemical
properties in the structure of hydroxyapatite crystal up to
impede its formation [74].
In conclusion, multiple physical, chemical, and bio-
logical mechanisms are involved in tissue regeneration
in vitro and in vivo using biomaterials [75]. The three-
dimensionality, the biocompatibility, and biodegradability
of hydrogel and its chemical surface characteristics, due
to addition of biofactors able to promote fundamental
cell biological processes, are needed to design successful
biomaterials for tissue regeneration applications. Currently,
attention is focused on the creation of scaffolds with
drug-delivery capacity. Scaffolds can represent biofactors’
reservoirs, are released during time, and are able to promote
cell growth and/or differentiation, allowing more rapid bone
healing. On the basis of our results, Sr2+ ion released
from CMCA hydrogel enhanced bone cell differentiation
of the PA2-E12 cell line, accelerating new bone matrix
formation. These data suggest that hADSCs, combined with
enriched biomaterials able to release in situ agents effective
in osteogenic differentiation, could represent a successful
strategy to develop innovative techniques for bone tissue
engineering.
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